Research Peptide Half-Lives: A Reference Guide

What Is Peptide Half-Life?

Half-life (t1/2) is the time required for the plasma concentration of a compound to decrease by 50% from its peak value. It is a fundamental pharmacokinetic parameter that governs how long a research compound remains at active concentrations in biological systems.

For peptides specifically, half-life is determined by several factors:

• •Enzymatic degradation — peptidases in plasma and tissues cleave peptide bonds; larger, more structurally protected peptides degrade more slowly
• •Molecular weight — smaller peptides are filtered more rapidly by the kidneys; larger peptides have longer plasma residence by virtue of slower glomerular filtration
• •Structural modifications — additions such as PEGylation, fatty acid chains, albumin-binding sequences (DAC), or protective C-terminal extensions dramatically extend half-life
• •Route of administration — IV delivers directly to plasma (fastest clearance onset); subcutaneous creates a slow-release depot; intranasal bypasses first-pass metabolism
• •Tissue binding — some peptides accumulate in specific tissues, creating a compartment with different kinetics than plasma

Understanding half-life matters for protocol design: it determines minimum effective dosing frequency, informs washout period selection, and helps distinguish plasma kinetics from downstream biological effect duration — which are often very different.

Plasma Half-Life Reference Table

Peptide-by-Peptide Analysis

BPC-157 — Short Plasma Half-Life, Prolonged Tissue Effects

BPC-157 (Body Protection Compound) is a 15-amino-acid pentadecapeptide with an estimated plasma half-life of 30 to 60 minutes. Despite this relatively rapid clearance, animal research consistently documents biological effects that persist well beyond what plasma half-life alone would predict.

The likely explanation is tissue-specific accumulation: BPC-157 has been shown to localise preferentially at sites of injury or inflammation in animal models, creating a local depot that sustains activity independently of plasma concentration. Research examining angiogenic, tendon-healing, gastric-protective, and anti-inflammatory effects has used administration frequencies that appear longer than plasma t1/2 would require, suggesting local tissue concentration drives sustained activity rather than plasma level maintenance.

TB-500 — Extended Clearance from Size

TB-500 is the synthetic analogue of Thymosin Beta-4, a naturally occurring 43-amino-acid protein. Its considerably larger molecular weight (approximately 4963 Da) relative to most research peptides results in slower renal glomerular filtration and an extended plasma presence measured in hours to days rather than minutes. Animal research protocols examining recovery and anti-inflammatory effects have used administration frequencies consistent with this extended half-life.

Semax and Selank — The Plasma-vs-Effect Divergence

Both Semax and Selank have extremely short plasma half-lives when administered intravenously — 1 to 5 minutes. Both were engineered with a C-terminal Pro-Gly-Pro sequence to extend this slightly by protecting the C-terminus from carboxypeptidase activity. Intranasal administration extends effective duration further via mucosal depot formation and direct olfactory pathway delivery to the CNS.

The critical insight is the divergence between plasma half-life and effect duration. Semax's primary mechanism — BDNF upregulation — is a genomic/transcriptional effect. Once the BDNF gene is transcribed, BDNF protein production continues for 24 to 72 hours regardless of whether Semax is still present in plasma. Selank's inhibition of enkephalin-degrading enzymes similarly produces an effect that persists after the peptide clears: with the degrading enzyme occupied or inhibited, endogenous enkephalin levels remain elevated until new enzyme is synthesised.

This means both compounds can produce sustained research effects from a single administration despite their very short plasma presence — a pharmacodynamic profile unlike traditional small-molecule drugs where effect generally tracks plasma concentration.

Ipamorelin — Clean Two-Hour Duration

Ipamorelin has a well-characterised plasma half-life of approximately 2 hours. Unlike other GHRPs (GHRP-6, GHRP-2), it does not significantly stimulate cortisol, prolactin, or adrenocorticotrophic hormone at research-relevant doses, making it one of the most selective GH secretagogues studied. Its 2-hour half-life produces a discrete GH pulse that mirrors physiological pulsatile GH secretion patterns — appropriate for protocols studying the natural GH axis rather than continuous elevation.

CJC-1295 — The DAC Difference

CJC-1295 without DAC (Modified GRF 1-29) has four amino acid substitutions that protect it from DPP-IV cleavage at multiple positions. Despite these protections, its plasma half-life remains approximately 30 minutes — short enough to produce a GH pulse closely resembling the physiological GHRH response.

CJC-1295 with DAC adds a lysine-maleimide Drug Affinity Complex that covalently binds to circulating albumin. This single modification extends its half-life to 6 to 8 days, as confirmed in human pharmacokinetic data from Teichman et al. (2006). The albumin-bound peptide is slowly released over days, producing sustained GH and IGF-1 elevation. The trade-off versus the no-DAC form is the loss of discrete pulsatile GH release — the extended half-life produces a more continuous GH stimulus rather than mimicking natural GHRH pulses.

Tesamorelin — Engineered for Stability

Tesamorelin is a GHRH analogue where the natural GHRH(1-44) sequence is modified with a trans-3-hexenoic acid group at the N-terminus. This modification specifically blocks DPP-IV cleavage at the Tyr-Ala bond that rapidly degrades native GHRH (which has a plasma half-life of approximately 7 minutes). Tesamorelin's resulting half-life of 26 to 38 minutes is substantially longer, producing more sustained GH axis stimulation per dose.

Retatrutide — Long-Acting Triple Agonist

Retatrutide is a triple agonist of GIP, GLP-1, and glucagon receptors, engineered with a C18 fatty diacid modification via a linker that enables albumin binding — the same engineering strategy used in other long-acting GLP-1 receptor agonists. This modification produces a terminal half-life of approximately 5 to 6 days, enabling once-weekly dosing in research protocols. The extended half-life results from fatty acid-mediated albumin association slowing both renal filtration and enzymatic degradation.

GHK-Cu — Rapid Plasma, Tissue-Level Effects

GHK-Cu has extremely rapid plasma clearance — the tripeptide is metabolised within minutes in circulation. However, its biological effects operate through a different mechanism: the copper ion delivered by GHK is incorporated into copper-dependent tissue enzymes (superoxide dismutase, lysyl oxidase, cytochrome c oxidase), and the GHK tripeptide itself has affinity for extracellular matrix components. The biological effects on collagen synthesis, wound healing gene expression, and antioxidant capacity persist substantially beyond plasma clearance because they are mediated by tissue-level enzymatic and transcriptional changes, not circulating peptide concentration.

Implications for Research Protocol Design

Half-life determines minimum dosing frequency for maintaining steady-state plasma exposure, but it does not directly predict effect duration. Three questions guide protocol design:

1. What is the target mechanism?

Direct receptor agonism (Ipamorelin, CJC-1295, Retatrutide) requires maintained plasma levels relative to the receptor's activation threshold. Transcriptional and neurotrophic effects (BDNF from Semax, collagen synthesis from GHK-Cu) persist long beyond plasma clearance because gene expression continues independently.

2. What is the desired exposure pattern?

Pulsatile GH secretion research is best served by short-half-life GHRPs (Ipamorelin) and GHRH analogues (CJC-1295 no DAC). Sustained GH elevation research is better served by long-half-life forms (CJC-1295 DAC, Tesamorelin multiple daily doses). The pattern matters as much as the total dose.

3. What washout period is appropriate?

For short-half-life peptides (Semax, Selank, BPC-157), washout is effectively complete within 24 hours of the last dose. For long-half-life compounds (CJC-1295 DAC, Retatrutide), complete washout requires approximately five times the half-life — meaning 30 to 40 days for full clearance.

Storage Stability vs Plasma Half-Life

Half-life refers exclusively to in-vivo kinetics after administration. Storage stability is a separate property entirely. Lyophilised peptides stored at -20 degrees Celsius remain stable for 12 to 24 months regardless of their plasma half-life. Reconstituted peptides stored at 2-8 degrees Celsius in bacteriostatic water are stable for up to 4 weeks.

Peptides with the shortest plasma half-lives (Semax, Selank, KPV) are not inherently less stable in storage — lyophilised stability is governed by the solid-state chemistry of the dry powder, not the in-solution or in-vivo kinetics. Freeze-thaw cycling reduces reconstituted peptide integrity across all compounds; minimise freeze-thaw cycles regardless of half-life.

See also: Peptide Storage Guide | How to Reconstitute Peptides | Selank vs Semax Comparison

Disclaimer: All information is for educational and in-vitro laboratory research purposes only. Not intended as medical advice or guidance for human use.